Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) Research & Development (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Research & Development readings, the most recent being $493000.0 for Q4 2017.

  • On a quarterly basis, Research & Development fell 42.41% to $493000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $2.0 million, a 80.62% decrease, with the full-year FY2024 number at $52.0 million, up 71.43% from a year prior.
  • Research & Development hit $493000.0 in Q4 2017 for Eledon Pharmaceuticals, down from $517000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $10.6 million in Q1 2015 to a low of $479000.0 in Q1 2017.
  • Median Research & Development over the past 5 years was $3.2 million (2014), compared with a mean of $3.7 million.
  • Biggest five-year swings in Research & Development: skyrocketed 200.57% in 2015 and later crashed 93.96% in 2017.
  • Eledon Pharmaceuticals' Research & Development stood at $4.3 million in 2013, then dropped by 12.53% to $3.8 million in 2014, then skyrocketed by 103.29% to $7.7 million in 2015, then tumbled by 88.93% to $856000.0 in 2016, then tumbled by 42.41% to $493000.0 in 2017.
  • The last three reported values for Research & Development were $493000.0 (Q4 2017), $517000.0 (Q3 2017), and $533000.0 (Q2 2017) per Business Quant data.